Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Drug Induced Sleep Endoscopy (DISERT)
Obstructive Sleep Apnea
About this trial
This is an interventional diagnostic trial for Obstructive Sleep Apnea focused on measuring Drug-induced sleep endoscopy, Dexmedetomidine, Airway collapsibility, Propofol
Eligibility Criteria
Inclusion Criteria:
- Apnea-Hypopnea Index (AHI) of 15-30.
- Men and women, age 18-65 years, Body Mass Index (BMI) < 35 Kg/m2,
- Awake oxygen saturation > 95%
- Able to read and sign the consent form
Exclusion Criteria:
- Chronic Obstructive Pulmonary Disease (COPD)
- Liver disease (Child Pugh 1-3)
- History of chronic use of sedatives, narcotics, alcohol or illicit drugs,
- History of 1st and 2nd degree heart block (not paced),
- Left Ventricular Ejection Fraction (LVEF) < 50%,
- Allergy to propofol or Dexmedetomidine,
- OSHAS (Obstructive sleep apnea/hypopnea syndrome) surgical failure patients
- Pregnant women.
Sites / Locations
- U.O.C. Otorinolaringoiatria Ospedale Di Barletta
Arms of the Study
Arm 1
Arm 2
Other
Other
Propofol group
Dexmedetomidine group
Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient . The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group
For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.